193 related articles for article (PubMed ID: 15672706)
1. Topical 0.25% methotrexate gel in a hydrogel base for palmoplantar psoriasis.
Kumar B; Sandhu K; Kaur I
J Dermatol; 2004 Oct; 31(10):798-801. PubMed ID: 15672706
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate iontophoresis versus coal tar ointment in palmoplantar psoriasis: A pilot study.
Haseena K; George S; Riyaz N; Sasidharanpillai S; Puthussery PV
Indian J Dermatol Venereol Leprol; 2017; 83(5):569-573. PubMed ID: 28731017
[TBL] [Abstract][Full Text] [Related]
3. Management of psoriasis vulgaris with methotrexate 0.25% in a hydrophilic gel: a placebo-controlled, double-blind study.
Syed TA; Hadi SM; Qureshi ZA; Nordstrom CG; Ali SM
J Cutan Med Surg; 2001; 5(4):299-302. PubMed ID: 11907839
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study.
Janagond AB; Kanwar AJ; Handa S
J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e384-9. PubMed ID: 23066720
[TBL] [Abstract][Full Text] [Related]
5. The treatment of psoriasis vulgaris: 1% topical methotrexate gel.
Eskicirak B; Zemheri E; Cerkezoglu A
Int J Dermatol; 2006 Aug; 45(8):965-9. PubMed ID: 16911386
[TBL] [Abstract][Full Text] [Related]
6. Combination Topical PUVAsol with Methotrexate Versus Methotrexate in the Treatment of Palmoplantar Psoriasis.
Karn D; Kc S
Kathmandu Univ Med J (KUMJ); 2016 Oct.-Dec.; 14(56):362-366. PubMed ID: 29336426
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
Papp K; Thaçi D; Marcoux D; Weibel L; Philipp S; Ghislain PD; Landells I; Hoeger P; Kotkin C; Unnebrink K; Seyger M; Williams D
Lancet; 2017 Jul; 390(10089):40-49. PubMed ID: 28478975
[TBL] [Abstract][Full Text] [Related]
8. A Comparative Study of the Effectiveness and Safety of Topical Calcipotriol and Topical Methotrexate in Chronic Plaque Psoriasis.
Das K; Ranjan R; Kumar P; Chandra S
Cureus; 2024 May; 16(5):e59878. PubMed ID: 38854231
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Efficacy and Safety of Apremilast and Methotrexate in Patients with Palmoplantar Psoriasis: A Randomized Controlled Trial.
Kt S; Thakur V; Narang T; Dogra S; Handa S
Am J Clin Dermatol; 2021 May; 22(3):415-423. PubMed ID: 33712987
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate monotherapy versus methotrexate and apremilast combination therapy in the treatment of palmoplantar psoriasis: A prospective, randomised, assessor-blinded, comparative study.
Hassanandani T; Panda M; Jena AK; Raj C
Indian J Dermatol Venereol Leprol; 2023; 89(2):213-220. PubMed ID: 35841363
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clobetasol propionate cream plus coal tar vs. topical psoralen and solar ultraviolet A therapy in palmoplantar psoriasis.
Khandpur S; Sharma VK
Clin Exp Dermatol; 2011 Aug; 36(6):613-6. PubMed ID: 21507036
[TBL] [Abstract][Full Text] [Related]
12. Calcipotriol versus coal tar: a prospective randomized study in stable plaque psoriasis.
Sharma V; Kaur I; Kumar B
Int J Dermatol; 2003 Oct; 42(10):834-8. PubMed ID: 14521705
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of efficacy and tolerability of apremilast and methotrexate in patients of moderate-to-severe palmoplantar psoriasis: A randomized, parallel, open-label clinical trial.
Wagh M; Mukhi J; Sontakke S; Dhok A; Turankar A; Kalikar M
Indian J Pharmacol; 2023; 55(6):356-362. PubMed ID: 38174531
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India.
Sandhu K; Kaur I; Kumar B; Saraswat A
J Dermatol; 2003 Jun; 30(6):458-63. PubMed ID: 12810993
[TBL] [Abstract][Full Text] [Related]
15. Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis.
Lin YK; Chang CJ; Chang YC; Wong WR; Chang SC; Pang JH
Arch Dermatol; 2008 Nov; 144(11):1457-64. PubMed ID: 19015420
[TBL] [Abstract][Full Text] [Related]
16. Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study.
Reich K; Graff O; Mehta N
Br J Dermatol; 2016 Jun; 174(6):1277-81. PubMed ID: 26800106
[TBL] [Abstract][Full Text] [Related]
17. Iontophoretic delivery of methotrexate in the treatment of palmar psoriasis: A randomised controlled study.
Andanooru Chandrappa NK; Channakeshavaiah Ravikumar B; Rangegowda SM
Australas J Dermatol; 2020 May; 61(2):140-146. PubMed ID: 31944270
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study.
Leonardi C; Maari C; Philipp S; Goldblum O; Zhang L; Burkhardt N; Ball S; Mallbris L; Gonzalez P; Fernández-Peñas P; Puig L
J Am Acad Dermatol; 2018 Nov; 79(5):824-830.e2. PubMed ID: 29803904
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of concomitant use of PUVA and methotrexate in disease clearance time in plaque type psoriasis.
Shehzad T; Dar NR; Zakria M
J Pak Med Assoc; 2004 Sep; 54(9):453-5. PubMed ID: 15518366
[TBL] [Abstract][Full Text] [Related]
20. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
